Acute Porphyria Drug Database

J07AM51 - Tetanus Toxoid, Combinations with Diphtheria Toxoid
Propably not porphyrinogenic
PNP

Rationale
Based on the pharmacokinetics of the tetanus toxoid, combinations with diphtheria toxoid vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Purified tetanus toxoid and diphtheria toxoid.
Therapeutic characteristics
The tetanus- and diphtheria –toxoid combination vaccine is indicated for booster vaccination against diphtheria and tetanus of individuals from the age of five years onwards. It is administered as a single intramuscular injection.
Metabolism and pharmacokinetics
The tetanus toxoid, combinations vaccine is not metabolized by the cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. Norwegian medicines agency. Summary of Product Characteristics (SPC). diTeBooster. #1868

Similar drugs
Explore alternative drugs in similar therapeutic classes J07A / J07AM or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙